1BP-LSD
Pharmaceutical compound
From Wikipedia, the free encyclopedia
1BP-LSD, also known as 1-(3-(tetramethyldioxaborolane)propionyl)-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1] It is thought to be a prodrug of LSD.[1] The drug was encountered online as a novel designer drug in December 2025.[1] 1BP-LSD has been sold in the form of blotter containing 175 and 200 μg per tab.[1] It has been said to be considered to be the official legal successor of 1S-LSD, which was banned in Germany soon before 1BP-LSD's appearance.[1] The effects of 1BP-LSD are said to be similar to those of 1S-LSD and to include visual changes, altered perception of time and space, heightened emotions, and increased creativity.[1] 1BP-LSD is not an explicitly controlled substance in the United States[2] or in Canada.[3]
- None
| Clinical data | |
|---|---|
| Other names | 1-(3-(Tetramethyldioxa-borolane)propionyl)-LSD |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C37H48BN3O4 |
| Molar mass | 609.62 g·mol−1 |
| 3D model (JSmol) | |
| |
| |